PT  - JOURNAL ARTICLE
AU  - Patricia Macedo
AU  - Joann Rhodes
AU  - Iain Kilty
AU  - Peter Barnes
AU  - Louise Donnelly
TI  - p38 MAPK inhibitors in COPD
DP  - 2012 Sep 01
TA  - European Respiratory Journal
PG  - P3714
VI  - 40
IP  - Suppl 56
4099  - http://erj.ersjournals.com/content/40/Suppl_56/P3714.short
4100  - http://erj.ersjournals.com/content/40/Suppl_56/P3714.full
SO  - Eur Respir J2012 Sep 01; 40
AB  - p38 MAPK signalling upregulates inflammation and is known to be increased in COPD. This study investigated whether p38 inhibitors PF75 and PF32 suppressed release of inflammatory cytokines from macrophage-lineage cells.Peripheral blood mononuclear cells (PBMC) and monocyte-derived macrophages (MDM) were isolated from non-smokers (NS), smokers (S) and COPD patients. Cells were pre-treated with either p38 inhibitor or dexamethasone (DEX) prior to stimulation with LPS. Cell media was harvested at 24h and cytokine release (IL-6, CXCL8, IL-10 and TNF) measured by ELISA.Both p38 inhibitors and DEX suppressed cytokine release in a concentration-dependent manner in PBMC and MDM. There were no differences between subject groups.View this table:EC50 values (nM) for DEX, PF75 and PF32 on cytokine releasep38 inhibitors suppress release of inflammatory cytokines and may have a therapeutic role in COPD.